How can researchers identify participants’ overall level of suggestibility and then focus on the minimization of this characteristic to solve the issue of suggestibility in clinical trial?
Mark P. Wade, Executive Director, Life Sciences at TransPerfect shares his thoughts on the ISOQOL 25th Annual Conference in Dublin. Hear what professionals that live and breathe Clinical Outcome Assessment (COA) measures learned from this event.
These recent events stressed the importance of the use of an electronic content management system and striving for a paperless environment. Read key take-aways from attendees at these events regarding what the future of TMF could look like.
The translation process for clinical trials, regulatory affairs, and other high-risk pharmaceutical documentation is historically manual and time-consuming. Learn how companies can transform the translation process using technology and artificial intelligence to work more efficiently and get drugs to market faster.
Digital innovations and their emerging technologies, such as artificial intelligence (AI), advanced analytics, and cloud-based computing, are transforming industries and markets across the world as they offer novel ways to boost R&D, increase product quality and safety, and ultimately improve customer satisfaction.
With novel therapies being launched there is a shift in data and evidence requirements as well. How can you be sure you are keeping up with the real-world evidence demands?
Compared to conventional approaches, a model-based approach to enrollment forecasting provides a more realistic assessment of the possible risks and outcomes for any given scenario, by accounting for the nonlinearity and randomness of real-life enrollment processes. In addition, a model-based approach offers many more advantages other than more realistic expectations.
This article will provide helpful pointers from Paul Terrill, Director of Strategic Consulting at Cytel to ensure smooth communication between statistical and clinical stakeholders.
IN 2018 there were many changes, trends, regulations and priorities that shaped the direction of the clinical research and drug development fields. In this paper, WCG experts share what they anticipate in 2019, and what everyone should be prepared for as we approach another year of change.
How a diagnostics startup drastically reduced timelines and costs, and easily shared data across dispersed sites.
|
|
|
|
|
|
|
|
|